ArQule Stock Price, News & Analysis (NASDAQ:ARQL)

$1.84 +0.05 (+2.79 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.84
Today's Range$1.76 - $1.84
52-Week Range$0.92 - $1.98
Volume217,871 shs
Average Volume179,940 shs
Market Capitalization$164.76 million
P/E Ratio-4.60
Dividend YieldN/A
Beta1.48

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorBiotechnology & Medical Research - NEC
SymbolNASDAQ:ARQL
CUSIP04269E10
Phone+1-781-9940300

Debt

Debt-to-Equity Ratio2.33%
Current Ratio3.45%
Quick Ratio3.45%

Price-To-Earnings

Trailing P/E Ratio-4.6
Forward P/E Ratio-4.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.71 million
Price / Sales34.03
Cash FlowN/A
Price / CashN/A
Book Value$0.33 per share
Price / Book5.58

Profitability

Trailing EPS($0.40)
Net Income$-22,710,000.00
Net MarginsN/A
Return on Equity-199.07%
Return on Assets-86.38%

Miscellaneous

Employees35
Outstanding Shares87,110,000

ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. During the same period last year, the firm earned ($0.08) EPS. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for ArQule.

Where is ArQule's stock going? Where will ArQule's stock price be in 2018?

3 equities research analysts have issued 1 year price targets for ArQule's shares. Their predictions range from $3.00 to $5.00. On average, they expect ArQule's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for ArQule.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

  • Patrick J. Zenner, Independent Chairman of the Board (Age 70)
  • Peter S. Lawrence, President, Chief Operating Officer (Age 52)
  • Paolo Pucci, Chief Executive Officer, Director (Age 56)
  • Robert J. Weiskopf, Chief Financial Officer, Treasurer (Age 62)
  • Brian Schwartz M.D., Chief Medical Officer (Age 53)
  • Timothy C. Barabe, Independent Director (Age 64)
  • Susan L. Kelley M.D., Independent Director (Age 62)
  • Ronald M. Lindsay Ph.D., Independent Director (Age 67)
  • Michael D. Loberg Ph.D., Independent Director (Age 67)
  • William G. Messenger D. Min., Independent Director (Age 54)

Who owns ArQule stock?

ArQule's stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (18.87%), Renaissance Technologies LLC (2.64%), Deutsche Bank AG (0.27%), Virtu Financial LLC (0.15%) and Millennium Management LLC (0.11%). View Institutional Ownership Trends for ArQule.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, Deutsche Bank AG, Virtu Financial LLC and Millennium Management LLC. View Insider Buying and Selling for ArQule.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.84.

How big of a company is ArQule?

ArQule has a market capitalization of $164.76 million and generates $4.71 million in revenue each year. The biotechnology company earns $-22,710,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. ArQule employs 35 workers across the globe.

How can I contact ArQule?

ArQule's mailing address is 1 Wall St, BURLINGTON, MA 01803-4769, United States. The biotechnology company can be reached via phone at +1-781-9940300 or via email at [email protected]


MarketBeat Community Rating for ArQule (ARQL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ArQule (NASDAQ:ARQL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00N/AN/AN/A
Price Target Upside: 139.52% upsideN/AN/AN/A

ArQule (NASDAQ:ARQL) Consensus Price Target History

Price Target History for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ:ARQL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Roth CapitalInitiated CoverageBuy -> Buy$5.00 -> $5.00MediumView Rating Details
2/8/2018B. RileySet Price TargetBuy$3.00LowView Rating Details
12/14/2017Needham & Company LLCUpgradeHold -> BuyHighView Rating Details
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

ArQule (NASDAQ:ARQL) Earnings History and Estimates Chart

Earnings by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ ARQL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.09)N/AView Earnings Details
11/9/2017Q3 2017($0.11)($0.09)ViewN/AView Earnings Details
8/4/2017Q2 2017($0.11)($0.10)ViewN/AView Earnings Details
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.19)($0.14)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.20)($0.18)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.21)($0.22)ViewN/AView Earnings Details
3/2/2010Q4 2009($0.25)($0.22)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.26)($0.19)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.23)($0.22)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.21)($0.23)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.27)($0.22)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.42)($0.26)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.38)($0.37)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.35)($0.32)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.31)($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ArQule (NASDAQ:ARQL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.05)($0.05)($0.05)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.07)($0.07)($0.07)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ArQule (NASDAQ ARQL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 53.96%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ ARQL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/7/2017Paolo PucciCEOBuy1,101$1.15$1,266.15404,194View SEC Filing  
9/6/2017Paolo PucciCEOBuy16,397$1.15$18,856.55403,093View SEC Filing  
9/5/2017Paolo PucciCEOBuy19,156$1.14$21,837.84386,696View SEC Filing  
8/29/2017Paolo PucciCEOBuy300$1.05$315.00367,540View SEC Filing  
8/28/2017Paolo PucciCEOBuy2,970$1.05$3,118.50367,240View SEC Filing  
8/25/2017Paolo PucciInsiderBuy9,492$1.05$9,966.60363,569View SEC Filing  
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04132,142View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34128,423View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28257,280View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80255,997View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90254,889View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00232,280View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00227,280View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ArQule (NASDAQ ARQL) News Headlines

Source:
DateHeadline
ArQule (ARQL) Coverage Initiated at Roth CapitalArQule (ARQL) Coverage Initiated at Roth Capital
www.americanbankingnews.com - February 22 at 3:46 PM
ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018 - Business Wire (press release)ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018 - Business Wire (press release)
www.businesswire.com - February 22 at 8:44 AM
ArQule (ARQL) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowArQule (ARQL) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:02 PM
ArQule, Inc. to Post Q1 2018 Earnings of ($0.05) Per Share, B. Riley Forecasts (ARQL)ArQule, Inc. to Post Q1 2018 Earnings of ($0.05) Per Share, B. Riley Forecasts (ARQL)
www.americanbankingnews.com - February 14 at 9:24 AM
 Brokerages Anticipate ArQule, Inc. (ARQL) to Post -$0.09 EPS Brokerages Anticipate ArQule, Inc. (ARQL) to Post -$0.09 EPS
www.americanbankingnews.com - February 10 at 11:10 AM
Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In ChinaBlog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China
finance.yahoo.com - February 9 at 9:38 AM
ArQule (ARQL) Given a $3.00 Price Target at B. RileyArQule (ARQL) Given a $3.00 Price Target at B. Riley
www.americanbankingnews.com - February 8 at 9:28 PM
ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018
finance.yahoo.com - February 8 at 8:29 AM
Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in ChinaRoivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
finance.yahoo.com - February 7 at 9:45 AM
BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In ChinaBRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China
finance.yahoo.com - February 7 at 9:45 AM
ArQule (ARQL) Earns Buy Rating from Analysts at B. RileyArQule (ARQL) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - February 2 at 2:33 PM
ArQule (ARQL) Stock Rating Lowered by Zacks Investment ResearchArQule (ARQL) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 10 at 4:40 PM
-$0.09 EPS Expected for ArQule, Inc. (ARQL) This Quarter-$0.09 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - January 7 at 9:58 AM
Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%
finance.yahoo.com - December 28 at 9:54 AM
 Analysts Anticipate ArQule, Inc. (ARQL) Will Post Earnings of -$0.09 Per Share Analysts Anticipate ArQule, Inc. (ARQL) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - December 22 at 3:04 AM
ArQule (ARQL) Upgraded at Needham & Company LLCArQule (ARQL) Upgraded at Needham & Company LLC
www.americanbankingnews.com - December 14 at 9:02 AM
ArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor DerazantinibArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor Derazantinib
www.rttnews.com - November 21 at 4:36 PM
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic CholangiocarcinomaArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
finance.yahoo.com - November 21 at 4:36 PM
ArQule, Inc. (ARQL) Rating Increased to Sell at ValuEngineArQule, Inc. (ARQL) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - November 18 at 12:46 AM
 Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.09 Earnings Per Share Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - November 15 at 7:30 PM
ArQule, Inc. (ARQL) Upgraded by Zacks Investment Research to "Buy"ArQule, Inc. (ARQL) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - November 15 at 5:06 PM
Edited Transcript of ARQL earnings conference call or presentation 9-Nov-17 2:00pm GMTEdited Transcript of ARQL earnings conference call or presentation 9-Nov-17 2:00pm GMT
finance.yahoo.com - November 10 at 6:51 PM
ArQule, Inc. (ARQL) Announces Quarterly  Earnings Results, Beats Estimates By $0.02 EPSArQule, Inc. (ARQL) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Cancer Immunotherapy Technology Projected to Create Further GrowthCancer Immunotherapy Technology Projected to Create Further Growth
www.bizjournals.com - November 9 at 5:12 PM
ArQule Reports Third Quarter 2017 Financial ResultsArQule Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:12 PM
ArQule, Inc. to Host Earnings CallArQule, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 5:12 PM
ArQule reports 3Q lossArQule reports 3Q loss
finance.yahoo.com - November 9 at 5:12 PM
Is It Time To Buy ArQule Inc (ARQL)?Is It Time To Buy ArQule Inc (ARQL)?
finance.yahoo.com - November 9 at 5:12 PM
ArQule Announces $9.5 Million Private Placement of Preferred StockArQule Announces $9.5 Million Private Placement of Preferred Stock
finance.yahoo.com - November 8 at 6:17 PM
ArQule (ARQL) Announces FDA Granted Rare Pediatric Disease Designation to its Miransertib for Treatment of Proteus SyndromeArQule (ARQL) Announces FDA Granted Rare Pediatric Disease Designation to its Miransertib for Treatment of Proteus Syndrome
www.streetinsider.com - November 1 at 4:36 PM
FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus SyndromeFDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
finance.yahoo.com - November 1 at 4:36 PM
ArQule, Inc. (ARQL) Set to Announce Quarterly Earnings on MondayArQule, Inc. (ARQL) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017
finance.yahoo.com - October 26 at 10:16 AM
ArQule (ARQL) and Its Peers Critical ContrastArQule (ARQL) and Its Peers Critical Contrast
www.americanbankingnews.com - October 20 at 4:26 PM
BRIEF-Arqule announces $15.7 mln private placement of common stockBRIEF-Arqule announces $15.7 mln private placement of common stock
www.businessinsider.com - October 17 at 2:56 AM
ArQule Announces $15.7 Million Private Placement of Common StockArQule Announces $15.7 Million Private Placement of Common Stock
finance.yahoo.com - October 16 at 4:53 PM
ArQule Announces $15.7 Million Private Placement of Common StockArQule Announces $15.7 Million Private Placement of Common Stock
finance.yahoo.com - October 16 at 4:53 PM
Zacks Investment Research Lowers ArQule, Inc. (ARQL) to HoldZacks Investment Research Lowers ArQule, Inc. (ARQL) to Hold
www.americanbankingnews.com - October 10 at 5:46 PM
Zacks: Brokerages Expect ArQule, Inc. (ARQL) to Announce -$0.12 EPSZacks: Brokerages Expect ArQule, Inc. (ARQL) to Announce -$0.12 EPS
www.americanbankingnews.com - October 7 at 10:28 AM
ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
finance.yahoo.com - September 19 at 4:03 PM
ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.12 Per ShareArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - September 18 at 4:28 PM
Insider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of StockInsider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of Stock
www.americanbankingnews.com - September 7 at 1:46 PM
ArQule, Inc. (ARQL) CEO Paolo Pucci Acquires 19,156 SharesArQule, Inc. (ARQL) CEO Paolo Pucci Acquires 19,156 Shares
www.americanbankingnews.com - September 6 at 1:38 PM
ArQule, Inc. (NASDAQ:ARQL) to Post FY2017 Earnings of ($0.44) Per Share, Leerink Swann ForecastsArQule, Inc. (NASDAQ:ARQL) to Post FY2017 Earnings of ($0.44) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 10 at 1:50 PM
Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMTEdited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT
finance.yahoo.com - August 4 at 9:46 PM
ArQules (ARQL) CEO Paolo Pucci on Q2 2017 Results - Earnings Call TranscriptArQule's (ARQL) CEO Paolo Pucci on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 4:23 PM
ArQule Reports Second Quarter 2017 Financial ResultsArQule Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 4:23 PM
ArQule reports 2Q lossArQule reports 2Q loss
finance.yahoo.com - August 4 at 4:23 PM
ArQule, Inc. (ARQL) Announces  Earnings Results, Beats Estimates By $0.01 EPSArQule, Inc. (ARQL) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 4 at 3:33 PM
ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.11 Per ShareArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - July 25 at 12:25 PM

SEC Filings

ArQule (NASDAQ:ARQL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ArQule (NASDAQ:ARQL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ArQule (NASDAQ ARQL) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.